Design of a human monoclonal antibody-informed dengue vaccine

描述（由申请人提供）：尽管是最重要的蚊媒病毒性疾病，但目前还没有登革热疫苗。登革病毒（DENV）有四种不同的血清型，并且针对一种血清型的交叉反应性抗体可以增强其他血清型对携带Fc受体的细胞（例如与人类严重疾病相关的巨噬细胞）的感染。安全有效的疫苗应诱导针对所有四种DENV血清型的强交叉保护性中和抗体，同时最大限度地减少只会增强感染和疾病严重程度的非中和交叉反应性抗体。因此，最佳疫苗应仅包括将诱导强中和抗体的那些抗原区域，而不包括诱导非中和抗体的抗原区域。该项目的中心目的是研究仅含有将诱导强的、广泛中和的DENV抗体应答的那些表位的疫苗将是安全和有效的假设。为了实现这一中心目标，该项目提出通过使用来自针对表面E蛋白的独特人单克隆抗DENV抗体的研究的见解来改变当前DENV疫苗研究的范式，以在小鼠模型中设计，表征和测试嵌合疫苗。第一个具体目标是设计含有DENV表位的黄病毒E蛋白嵌合体，并表征其折叠、组装和功能。由于我们用人单克隆抗体的结果表明，重要的中和DENV表位是构象敏感的，相关的黄病毒黄热病将被用作构建嵌合体的支架。我们将在黄热病17D疫苗株E蛋白中引入特异性DENV表位，产生嵌合E蛋白、病毒样颗粒和感染性病毒，并确定这些E蛋白嵌合体是否仍然被我们的人抗DENV单克隆抗体识别。第二个具体目的是在小鼠模型中评估含有DENV表位的黄病毒E蛋白嵌合体的抗原性，并在体外测定血清中结合、中和和增强抗DENV抗体的存在。第三个具体目标是确定含有DENV表位的黄病毒E蛋白嵌合体是否会在小鼠DENV攻击模型中产生保护性免疫应答。使用广泛接受的DENV感染的鼠模型提出了DENV的感染性攻击。这些目标的成功完成将创造一种DENV疫苗，该疫苗将诱导广泛中和抗体应答，同时最大限度地减少非中和增强抗体应答的诱导，最大限度地减少疫苗接受者患更严重疾病的风险。

DESCRIPTION (provided by applicant): Despite being the most important mosquito-transmitted viral disease, there is currently no vaccine for dengue. There are four distinct serotypes of dengue virus (DENV) and cross reactive antibodies to one serotype can enhance infection of other serotypes into Fc receptor-bearing cells such as macrophages correlating with severe disease in humans. A safe and effective vaccine should induce strong, cross protective neutralizing antibodies against all four DENV serotypes, while minimizing non-neutralizing cross reactive antibodies that will only serve to enhance infection and disease severity. Therefore, an optimal vaccine should include only those antigenic regions that will induce strongly neutralizing antibodies and none of the antigenic regions that induce non-neutralizing antibodies. The central aim of this project is to investigate the hypothesis that a vaccine containing only those epitopes that will induce a strong, broadly neutralizing DENV antibody response will be safe and effective. To accomplish this central aim, this project proposes to shift the current paradigm of DENV vaccine research by using insights derived from the study of unique human monoclonal anti-DENV antibodies against the surface E protein to design, characterize, and test a chimeric vaccine in a mouse model. The first specific aim is to design flavivirus E protein chimeras containing DENV epitopes, and characterize their folding, assembly, and functionality. As our results with human MAbs indicate that the important neutralizing DENV epitopes are conformationally sensitive, a related flavivirus, yellow fever will be used as a scaffold for constructing the chimeras. We will introduce specific DENV epitopes into the yellow fever 17D vaccine strain E protein, generate chimeric E protein, virus- like particles, and infectious virus and determine whether these E protein chimeras are still recognized by our human anti-DENV monoclonal antibodies. The second specific aim is to evaluate the antigenicity of flavivirus E protein chimeras containing DENV epitopes in a mouse model and assay serum for the presence of binding, neutralizing, and enhancing anti-DENV antibodies in vitro. The third specific aim is to determine if flavivirus E protein chimeras containing DENV epitopes will produce a protective immunological response in a mouse DENV challenge model. Infectious challenge with DENV is proposed using a widely accepted murine model of DENV infection. Successful completion of the aims will create a DENV vaccine that will induce a broadly neutralizing antibody response, while minimizing the induction of a non-neutralizing, enhancing antibody response, minimizing the risk of more severe disease in vaccine recipients.